A cell cycle automaton model for probing circadian patterns of anticancer drug delivery

Advanced Drug Delivery Reviews

Volumn 59, Issue 9-10, 2007, Pages 1036-1053

  Altinok, Atilla ^a   Lévi, Francis ^b,c,d   Goldbeter, Albert ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Anticancer medications; Cell cycle model; Chronopharmacology; Chronotherapy; Circadian rhythm

Indexed keywords

CELLS; ONCOLOGY; OPTIMIZATION; PHARMACODYNAMICS; TUMORS;

ANTICANCER MEDICATIONS; CANCER CHRONOTHERAPY; CELL CYCLE AUTOMATON MODELS; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM;

DRUG DELIVERY;

FLUOROURACIL;

AUTOMATION; CANCER THERAPY; CELL CYCLE; CELL CYCLE S PHASE; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; MODEL; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL SURVIVAL; CIRCADIAN RHYTHM; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS;

EID: 35148895523     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.09.022     Document Type: Review

References (39)

1. Fu L., Pelicano H., Liu J., Huang P., and Lee C.C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111 (2002) 41-50
2. Filipski E., King V.M., Li X., Granda T.G., Mormont M.C., Liu X., Claustrat B., Hastings M.H., and Levi F. Host circadian clock as a control point in tumor progression. J. Natl. Cancer Inst. 94 (2002) 690-697
3. Matsuo T., Yamaguchi S., Mitsui S., Emi A., Shimoda F., and Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 302 (2003) 255-259
4. Hirayama J., Cardone L., Doi M., and Sassone-Corsi P. Common pathways in circadian and cell cycle clocks: light-dependent activation of Fos/AP-1 in zebrafish controls CRY-1a and WEE-1. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10194-10199
5. Reddy A.B., Wong G.K.Y., O'Neill J., Maywood E.S., and Hastings M.H. Circadian clocks: neural and peripheral pacemakers that impact upon the cell division cycle. Mutat. Res. 574 (2005) 76-91
6. Smaaland R. Circadian rhythm of cell division. Prog. Cell Cycle Res. 2 (1996) 241-266
7. Bjarnason G.A., and Jordan R. Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. Prog. Cell Cycle Res. 4 (2000) 193-206
8. Bjarnason G.A., Jordan R.C.K., Wood P.A., Li Q., Lincoln D.W., Sothern R.B., Hrushesky W.J.M., and Ben-David Y. Circadian expression of clock genes in human oral mucosa and skin. Am. J. Pathol. 158 (2001) 1793-1801
9. Granda T.G., Liu X.H., Smaaland R., Cermakian N., Filipski E., Sassone-Corsi P., and Lévi F. Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J. 19 (2005) 304-306
10. Focan C. Circadian rhythms and cancer chemotherapy. Pharmacol. Ther. 67 (1995) 1-52
11. Lévi F. Chronopharmacology of anticancer agents. In: Redfern P.H., and Lemmer B. (Eds). Handbook of Experimental Pharmacology. Physiology and Pharmacology of Biological Rhythms vol. 125 (1997), Springer-Verlag, Berlin 299-331
12. Lévi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2 (2001) 307-315
13. Lévi F. From circadian rhythms to cancer chronotherapeutics. Chronobiol. Int. 19 (2002) 1-19
14. Mormont M.C., and Lévi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 97 (2003) 155-169
15. Goldbeter A., and Claude D. Time-patterned drug administration: Insights from a modeling approach. Chronobiol. Int. 19 (2002) 157-175
16. Goldbeter A. Biochemical Oscillations and Cellular Rhythms (1996), Cambridge Univ. Press, Cambridge, UK
17. Tyson J.J., and Novak B. Regulation of the eukaryotic cell cycle: molecular antagonism, hysteresis, and irreversible transitions. J. Theor. Biol. 210 (2001) 249-263
18. Novak B., and Tyson J.J. A model for restriction point control of the mammalian cell cycle. J. Theor. Biol. 230 (2004) 563-579
19. Qu Z., MacLellan W.R., and Weiss J.N. Dynamics of the cell cycle: checkpoints, sizers, and timers. Biophys. J. 88 (2003) 3600-3611
20. Smith J.A., and Martin L. Do cells cycle?. Proc. Natl. Acad. Sci. U. S. A. 70 (1973) 1263-1267
21. Brooks R.F., Bennett D.C., and Smith J.A. Mammalian cell cycles need two random transitions. Cell 19 (1980) 493-504
22. Cain S.J., and Chau P.C. Transition probability cell cycle model. I. Balanced growth. J. Theor. Biol. 185 (1997) 55-67
23. Halloy J., Bernard B.A., Loussouarn G., and Goldbeter A. Modeling the dynamics of human hair cycles by a follicular automaton. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8328-8333
24. Halloy J., Bernard B.A., Loussouarn G., and Goldbeter A. The follicular automaton model: effect of stochasticity and of synchronization of hair cycles. J. Theor. Biol. 214 (2002) 469-479
25. Metzger G., Massari C., Etienne M.C., Comisso M., Brienza S., Touitou Y., Milano G., Bastian G., Misset J.L., and Levi F. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin. Pharmacol. Ther. 56 (1994) 190-201
26. Zhang R., Lu Z., Liu T., Soong S.-J., and Diasio R.B. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res. 53 (1993) 2816-2822
27. Lévi F., Zidani R., Vannetzel J.M., Perpoint B., Focan C., Faggiuolo R., Chollet P., Garufi C., Itzhaki M., Dogliotti L., et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst. 86 (1994) 1608-1617
28. Lévi F., Zidani R., and Misset J.L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350 (1997) 681-686
29. Blagosklonny M.V., and Pardee A.B. Review. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 61 (2001) 4301-4305
30. Clairambault J., Michel P., and Perthame B. Circadian rhythm and tumour growth. C. R. Acad. Sci. (Paris) Ser. 1 342 (2006) 17-22
31. Basdevant C., Clairambault J., and Lévi F. Optimisation of time-scheduled regimen for anti-cancer drug infusion. Math. Model. Numer. Anal. 39 (2005) 1069-1086
32. Dibrov B.F., Zhabotinsky A.M., Neyfakh Y.A., Orlova M.P., and Churikova L.I. Mathematical model of cancer chemotherapy. Periodic schedules of phase-specific cytotoxic agent administration increasing the selectivity of therapy. Math. Biosci. 73 (1985) 1-31
33. Dibrov B.F. Resonance effect in self-renewing tissues. J. Theor. Biol. 192 (1998) 15-33
34. Agur Z. The effect of drug schedule on responsiveness to chemotherapy. Ann. N.Y. Acad. Sci. 504 (1986) 274-277
35. Agur Z., Arnon R., and Schechter B. Reduction of cytotoxicity to normal tissue by new regimens of cell-cycle phase-specific drugs. Math. Biosci. 92 (1988) 1-15
36. Agur Z., Arnon R., Sandak B., and Schechter B. Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration. Exp. Hematol. 19 (1991) 364-368
37. Ubezio P., Tagliabue G., Schechter B., and Agur Z. Increasing 1-β-d-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. Cancer Res. 54 (1994) 6446-6451
38. Webb G.F. Resonance phenomena in cell population chemotherapy models. Rocky Mt. J. Math. 20 (1990) 1195-1216
39. Andersen L.K., and Mackey M.C. Resonance in periodic chemotherapy: a case study of acute myelogenous leukemia. J. Theor. Biol. 209 (2001) 113-130